Relmada Therapeutics, Inc. (NASDAQ:RLMD) Expected to Post Earnings of -$1.21 Per Share

Wall Street brokerages expect that Relmada Therapeutics, Inc. (NASDAQ:RLMDGet Rating) will post earnings per share (EPS) of ($1.21) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Relmada Therapeutics’ earnings. The lowest EPS estimate is ($1.26) and the highest is ($1.12). Relmada Therapeutics reported earnings per share of ($1.34) during the same quarter last year, which would suggest a positive year-over-year growth rate of 9.7%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Relmada Therapeutics will report full-year earnings of ($5.15) per share for the current financial year, with EPS estimates ranging from ($5.25) to ($4.97). For the next year, analysts expect that the firm will post earnings of ($3.76) per share, with EPS estimates ranging from ($5.67) to ($2.50). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Relmada Therapeutics.

Relmada Therapeutics (NASDAQ:RLMDGet Rating) last issued its quarterly earnings results on Wednesday, March 23rd. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.20). During the same period in the previous year, the company posted ($1.28) EPS.

Several analysts have issued reports on RLMD shares. The Goldman Sachs Group cut their price objective on Relmada Therapeutics from $69.00 to $53.00 and set a “buy” rating on the stock in a report on Thursday, March 24th. SVB Leerink decreased their target price on shares of Relmada Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, December 20th. Finally, Zacks Investment Research upgraded shares of Relmada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 26th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Relmada Therapeutics currently has an average rating of “Buy” and an average target price of $38.11.

Relmada Therapeutics stock traded down $0.33 during midday trading on Tuesday, hitting $25.07. The company’s stock had a trading volume of 113,245 shares, compared to its average volume of 296,002. The business’s 50-day simple moving average is $22.40. Relmada Therapeutics has a 12 month low of $16.23 and a 12 month high of $40.00. The firm has a market capitalization of $737.89 million, a P/E ratio of -3.51 and a beta of 0.45.

In other Relmada Therapeutics news, Director Paul Edward Kelly sold 10,000 shares of the firm’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $30.04, for a total value of $300,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 11.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Byrne Asset Management LLC boosted its position in Relmada Therapeutics by 15.1% during the 1st quarter. Byrne Asset Management LLC now owns 6,675 shares of the company’s stock worth $180,000 after acquiring an additional 875 shares during the last quarter. apricus wealth LLC bought a new stake in Relmada Therapeutics in the 4th quarter valued at $765,000. Norges Bank bought a new stake in Relmada Therapeutics in the 4th quarter valued at $2,219,000. Walleye Capital LLC bought a new position in Relmada Therapeutics during the 4th quarter worth $469,000. Finally, BlackRock Inc. increased its position in Relmada Therapeutics by 14.5% during the 4th quarter. BlackRock Inc. now owns 1,385,235 shares of the company’s stock worth $31,211,000 after buying an additional 174,994 shares during the period. 52.89% of the stock is owned by institutional investors.

Relmada Therapeutics Company Profile (Get Rating)

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.

Featured Articles

Get a free copy of the Zacks research report on Relmada Therapeutics (RLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Relmada Therapeutics (NASDAQ:RLMD)

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.